Yakup Ergün· @dr_yakupergun · X·· 2 days agoScore70
Body · original
#ESMO26 | FINER
In HR+/HER2− mBC, ipatasertib + fulvestrant failed to demonstrate an OS benefit despite improving PFS (26.7 vs 25.8 mo; HR 1.14).
No OS benefit was observed in patients with AKT pathway alterations either (HR 1.14)!!!
I’m eagerly awaiting the presentation details to better understand why the PFS benefit did not translate into an OS advantage.
316 views · 1 like · 2 reposts · 0 replies
Conference abstracts
LBA14matched by Proffered paper 2: Breast cancer, early and advanced stage
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/
https://esmocongress.esmo.orgSource: Yakup Ergün · x.com